Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically confirmed non-small cell lung cancer (NSCLC) Meets 1 of the following stage criteria: Completely resected stage I-IIIB disease Underwent surgical resection > 4 weeks but ≤ 4 years ago Unresectable stage IIIA or IIIB disease AND previously treated with definitive radiotherapy or chemotherapy > 6 weeks ago Bronchoalveolar carcinomas allowed Clinically stable disease by chest x-ray or CT scan within the past 6 weeks No progressive disease No malignant pleural or pericardial effusions PATIENT CHARACTERISTICS: Age 18 to 80 Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Hemoglobin ≥ 9.0 g/dL Hepatic Bilirubin ≤ 2.5 times upper limit of normal (ULN) AST and ALT ≤ 2.5 times ULN No known history of infectious hepatitis Renal Creatinine ≤ 3 mg/dL Ionized calcium ≥ 0.9 mmol/L (may be replaced) Cardiovascular No known New York Heart Association class III-IV congestive heart failure No hemodynamically significant valvular heart disease No myocardial infarction within the past 6 months No active angina pectoris No uncontrolled ventricular arrhythmia No stroke within the past year No known cerebrovascular disease No other significant cardiac disease by echocardiogram, stress test, or risk assessment by cardiologist (for patients suspected of cardiac disease by history or physical exam) Immunologic No known HIV positivity No other immunosuppressive disorders, including chronic disorders Other Not pregnant Negative pregnancy test Potassium ≥ 3.0 mEq/L (may be replaced) Able to tolerate modest blood volume and electrolyte shifts during leukapheresis No other malignancy PRIOR CONCURRENT THERAPY: Biologic therapy Prior biologic therapy allowed Other concurrent biologic therapy allowed Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent steroids during and for 16 weeks after study treatment Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics Other Prior neoadjuvant or adjuvant therapy for surgically resected patients allowed No concurrent shorter courses of immunosuppressive medications during and for 16 weeks after study treatment No concurrent chronic immunosuppressive medications Concurrent cyclooxygenase-2 inhibitors allowed